• Depomed Inc., of Menlo Park, Calif., submitted a new drug application for Serada to the FDA. The extended-release formulation of gabapentin is in development to treat menopausal hot flashes. The company conducted three Phase III studies (BREEZE 1, 2 and 3), reporting in October 2011 that Serada achieved its primary BREEZE 3 endpoints at four weeks but faltered at 12 weeks, hitting the severity endpoint but failing to reduce frequency.